Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 6,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Medication Group Clear all

Conditions: Obesity, Healthy
Interventions: Ileocolonic-release conjugated bile acid, Placebo; Dietary Supplement · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Adverse Effects of Angiotensin-converting-enzyme Inhibitors, Hypotension
Interventions: ACE-I Cessation group, ACE-I Continuation group; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions: ZYNRELEF 200Mg-6Mg Extended-Release Solution; Drug
Lead sponsor: Dr. Yannis Raftopoulos; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Holyoke, Massachusetts

Conditions: Actinic Keratoses
Interventions: PEP005 (ingenol mebutate) Gel, Vehicle gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 17
States / cities: Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more

Conditions: Hepatitis B， Chronic, Hepatitis C
Interventions: Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire, Liver transient elastography (FibroScan), Liver Biopsy; Other · Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 99 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2034
U.S. locations: 2
States / cities: Baltimore, Maryland • Falls Church, Virginia

Conditions: Age-Related Macular Degeneration
Interventions: ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin; Drug
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Diabetes Mellitus
Interventions: Patient Activation, Provider Training, Quality Improvement, Community Outreach; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 6,209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 6
States / cities: Chicago, Illinois

Conditions: Meningococcal Immunisation (Healthy Volunteers)
Interventions: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 13 Years to 26 Years
Enrollment: 570 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more

Conditions: Cancer, Pain, Advanced Cancer
Interventions: Cancer Pain 101; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sjögren Syndrome
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dysmenorrhea, Menstrual Cramps
Interventions: Topical Analgesic with Camphor and Menthol; Dietary Supplement
Lead sponsor: Rael; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Hypertension
Interventions: Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Disability Physical, Cognitive Impairment
Interventions: Modified FE-SaLiR, Unmodified Chinese Medicine Exercise, Active Control; Behavioral
Lead sponsor: The University of Texas at San Antonio; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Critical Illness, Hyperglycemia
Interventions: Serum Lab testing; Other
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: 2 Years to 12 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes
Interventions: Peers LEAD, HLWD; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Obesity, Weight Loss, CHD - Coronary Heart Disease
Interventions: Exercise, Health Education, Exercise Compliance, Calorie-Restricted Diet, Behavioral Modification, Weight-Loss Compliance, Dietary Counseling; Other · Behavioral · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Alzheimer Disease
Interventions: NE3107, Placebo; Drug
Lead sponsor: BioVie Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD)
Interventions: Care4Today® Connect CAD-PAD Mobile Application; Device
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Aurora, Colorado • Jacksonville, Florida • Overland Park, Kansas + 2 more

Conditions: Functional Dyspepsia
Interventions: Glutamine, Placebo; Drug
Lead sponsor: David J. Cangemi; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Laparoscopic Hysterectomy and/or Laparoscopic Sacrocolpopexy
Interventions: Fleet Enema (sodium biphosphate and sodium phosphate); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Obesity, Overweight
Interventions: Standard behavioral treatment (SBT) for weight loss, SBT for weight loss using a PDA, SBT for weight loss using a PDA with feedback messages; Behavioral
Lead sponsor: Lora Burke; Other
Eligibility: 18 Years to 59 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COVID-19
Interventions: Sodium Pyruvate, Saline; Drug · Other
Lead sponsor: Cellular Sciences, inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Virginia Gardens, Florida • Springfield, Missouri

Conditions: Abscess
Interventions: oral trimethoprim/sulfamethoxazole, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 90 Days to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Asthma
Interventions: Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, Placebo; Drug
Lead sponsor: Cipla Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Medford, Oregon

Search by objective public record fields.

Effect of Bile Acids on Satiety, Cell Function and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype

ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

The HOPE Study: Characterizing Patients With Hepatitis B and C

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Improving Diabetes Care and Outcomes on the South Side of Chicago

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Cancer Pain 101: A Digital, Asynchronous Intervention of Pain Management in Advanced Cancer

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

A Single Group Study to Evaluate the Effects of a Topical Product on Cramps Associated With the Menstrual Cycle

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

FE-SaLiR: Function Improvement Exercise

Study of High Blood Sugars and Insulin in Hospitalized, Critically Ill Children

Peers EXCEL Trial to Improve Glycemic Control

Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)

A Phase 3 Study of NE3107 in Probable Alzheimer's Disease

A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population

A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

Mechanical Bowel Preparation Before Laparoscopic Hysterectomy and Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial

Improving Self-Monitoring in Weight Loss With Technology

Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage

BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient